查詢結果分析
來源資料
相關文獻
- 現今大腸癌之治療趨勢
- 大腸癌治療的展望--多學科整合(Multidisciplinary Approach)
- 一位大腸癌病人面對首次居家化學治療之護理經驗
- 談癌症治療的抗藥性
- Chemotherapy and Targeted Therapy in Colorectal Cancer: The Current Status
- 大腸癌病人決定接受標靶治療之決策過程
- 第二期大腸癌病人開刀後存活分析:著眼於化學治療--單一醫學中心的經驗
- 協助初次接受化療及術後腸造口存在個案之護理經驗
- 內科腫瘤治療之新進展
- Adjuvant Chemotherapy for High-risk Stage II Colon Cancer
頁籤選單縮合
題名 | 現今大腸癌之治療趨勢=Current Trends in the Treatment of Colorectal Cancer |
---|---|
作者 | 姚遠賢; 謝東呈; 蘇淑芬; 王守玉; Yao, Yuan-hsien; Shieh, Dong-chen; Su, Shu-fen; Wang, Shou-yu; |
期刊 | 弘光學報 |
出版日期 | 20111200 |
卷期 | 65 2011.12[民100.12] |
頁次 | 頁72-92 |
分類號 | 416.245 |
語文 | chi |
關鍵詞 | 大腸癌; 化學治療; 標靶治療; Colorectal cancer; Chemotherapy; Targeted therapy; |
中文摘要 | 根據世界衛生組織(WHO, 2010)指出大腸癌為世界癌症死亡的第二大主因。 全世界每年有超過11,000,000人被診斷出罹患癌症,在美國癌症盛行率排行榜高居第三位;在香港男性及女性癌症排行第二位;在台灣民國98年發生率為第二位,有4,531人死亡,死亡率則為第三位,顯示大腸癌的嚴重性是不容小覷,因此如何治療大腸癌及探討大腸癌可能致病原因,是目前臨床上重要的研究方向。現今大腸癌的治療以手術切除為主,化學治療為輔,但癌症後期存活率偏低及術後腸癌細胞易轉移,合併傳統化學藥物治療有嚴重的副作用等,使得病患治癒率低與復發率高。因此,開發新型藥物來輔助治療、延緩或抑制癌症發展是必需且急迫的。本文探討近來大腸癌的進展、致病機轉、診斷檢驗及治療,尤其探討針對癌細胞作用之標靶藥物的作用機轉、臨床試驗結果及副作用。提供社會大眾多加利用癌症篩檢、早期診斷、才能有更好的藥物治療,延長病患存活期及提高病患生活品質的基礎。 |
英文摘要 | According to the epidemiological studies in Taiwan in 2009, the incidence of colorectal cancer ranked the second and the mortality of colorectal cancer ranked the third among all cancer deaths. Therefore, the seriousness of colorectal cancer should not be underestimated. Nowadays how to treat colorectal cancer and to explore the possible causes of colorectal cancer remains the major point for research. In the late stage colorectal cancer, distant metastases are common and the survival rate is still low even after surgical excision. Thus, it is essential and urgent to develop new drugs which could delay or inhibit the progression of colorectal cancer. The progress in pathogenesis, diagnosis and treatment developed in targeted therapies lately on colorectal cancer will be discussed in this paper. We expect our paper can provide up-to-date colorectal cancer treatment for healthcare professionals and references for patients´ decision-making in choosing the best modality for colorectal cancer treatments. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。